First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical TrialMOLECULAR THERAPYIF122019-11-0149OAAI
Tumor immune profiling suggests synovial sarcoma but not desmoplastic small round cell tumor may respond to cancer immunotherapiesCANCER RESEARCHIF16.62018-10-011PRE
Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid TumorsMOLECULAR THERAPY-ONCOLYTICSIF02017-09-0137OAAI
Injection of the viroimmunotherapeutic oncolytic herpes virus rRp450 increases survival of orthotopic mouse models of Group 3 medulloblastoma and atypical teratoid/rhabdoid tumorsCANCER RESEARCHIF16.62016-04-040PRE
Checkpoinblockade enhances oncolytic herpes virotherapy in immunosuppressive sarcoma modelsCANCER RESEARCHIF16.62016-04-040PRE
To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic VirusesVIRUSES-BASELIF3.52016-02-0440OAAI
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in childrenMOLECULAR THERAPY-ONCOLYTICSIF02015-01-0112OAAI
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenMOLECULAR THERAPY-ONCOLYTICSIF02015-01-0120OAAI
The tumor immunologic microenvironment influences antitumor efficacy of oncolytic herpes simplex virotherapyCANCER RESEARCHIF16.62014-10-090PRE
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivityMOLECULAR THERAPY-ONCOLYTICSIF02014-01-0137OAAI